{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:19:48Z","timestamp":1792181988756,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004271","name":"Sapienza University of Rome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.numecd.2025.104110","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T02:32:23Z","timestamp":1746239543000},"page":"104110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dyslipidemia and statin use in people with HIV-1 infection: beyond the lipid-lowering effect"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-3309","authenticated-orcid":false,"given":"Gianluca","family":"Gazzaniga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Mezzaroma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.numecd.2025.104110_bib1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.numecd.2025.104110_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1046\/j.1525-1497.2002.20201.x","article-title":"Evaluation and management of dyslipidemia in patients with HIV infection","volume":"17","author":"Green","year":"2002","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.numecd.2025.104110_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/HIV.S275314","article-title":"Antiretroviral therapy-associated metabolic complications: review of the recent studies","volume":"12","author":"Thet","year":"2020","journal-title":"HIV AIDS Res Palliat Care"},{"key":"10.1016\/j.numecd.2025.104110_bib4","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04078","article-title":"Higher cardiovascular disease risks in people living with HIV: a systematic review and meta-analysis","volume":"14","author":"Zhu","year":"2024","journal-title":"J Glob Health"},{"issue":"4","key":"10.1016\/j.numecd.2025.104110_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cid\/ciy146","article-title":"Higher risk of abdominal obesity, elevated low-density lipoprotein cholesterol, and hypertriglyceridemia, but not of hypertension, in people living with human immunodeficiency virus (HIV): results from the Copenhagen comorbidity in HIV infection study","volume":"67","author":"Gelpi","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.numecd.2025.104110_bib6","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.numecd.2025.104110_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040365","article-title":"Human immunodeficiency virus impairs reverse cholesterol transport from macrophages","volume":"4","author":"Mujawar","year":"2006","journal-title":"PLoS Biol"},{"issue":"3","key":"10.1016\/j.numecd.2025.104110_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu108","article-title":"High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection","volume":"1","author":"Lo","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.numecd.2025.104110_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104039","article-title":"HIV-derived ssRNA binds to TLR8 to induce inflammation-driven macrophage foam cell formation","volume":"9","author":"Bernard","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.numecd.2025.104110_bib10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/infdis\/jir520","article-title":"Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients","volume":"204","author":"Burdo","year":"2011","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0000000000000566","article-title":"Oxidized LDL levels are increased in HIV infection and may drive monocyte activation","volume":"69","author":"Zidar","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.numecd.2025.104110_bib12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jacc.2023.04.050","article-title":"Dyslipidemia in human immunodeficiency virus disease: JACC review topic of the week","volume":"82","author":"Kalra","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.numecd.2025.104110_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044454","article-title":"Inflammation, coagulation and cardiovascular disease in HIV-infected individuals","volume":"7","author":"Duprez","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.numecd.2025.104110_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.20411\/pai.v2i3.218","article-title":"Prospective analysis of lipid composition changes with antiretroviral therapy and immune activation in persons living with HIV","volume":"2","author":"Belury","year":"2017","journal-title":"Pathog Immun"},{"key":"10.1016\/j.numecd.2025.104110_bib16","first-page":"1","article-title":"Managing dyslipidemia in HIV\/AIDS patients: challenges and solutions","volume":"7","author":"Husain","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"issue":"24","key":"10.1016\/j.numecd.2025.104110_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010345","article-title":"Trends in utilization of statin therapy and contraindicated statin use in HIV--Infected adults treated with antiretroviral therapy from 2007 through 2015","volume":"7","author":"Rosenson","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.numecd.2025.104110_bib19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"issue":"Suppl 2","key":"10.1016\/j.numecd.2025.104110_bib20","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1086\/367562","article-title":"Lipid abnormalities","volume":"36","author":"Dube","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib21","first-page":"199","article-title":"Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India","volume":"39","author":"Pujari","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.numecd.2025.104110_bib22","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.numecd.2025.104110_bib23","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.numecd.2025.104110_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/cid\/civ193","article-title":"Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257","volume":"60","author":"Ofotokun","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.numecd.2025.104110_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm1201-1327","article-title":"HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia","volume":"7","author":"Liang","year":"2001","journal-title":"Nat Med."},{"key":"10.1016\/j.numecd.2025.104110_bib26","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"issue":"12","key":"10.1016\/j.numecd.2025.104110_bib27","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1161\/ATVBAHA.110.213603","article-title":"Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin","volume":"30","author":"Lef\u00e8vre","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.numecd.2025.104110_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1590\/S1413-86702001000600007","article-title":"Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate","volume":"5","author":"Caramelli","year":"2001","journal-title":"Braz J Infect Dis"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.numecd.2025.104110_bib30","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.numecd.2025.104110_bib31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/QAD.0000000000003373","article-title":"Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV","volume":"37","author":"Jaschinski","year":"2023","journal-title":"AIDS"},{"issue":"16","key":"10.1016\/j.numecd.2025.104110_bib32","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1097\/00002030-200411050-00004","article-title":"The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro","volume":"18","author":"Caron","year":"2004","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.numecd.2025.104110_bib33","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.aids.0000233574.49220.de","article-title":"Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir","volume":"20","author":"Llibre","year":"2006","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.numecd.2025.104110_bib35","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s15010-018-1227-0","article-title":"A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017","volume":"47","author":"Gomez","year":"2019","journal-title":"Infection"},{"issue":"10","key":"10.1016\/j.numecd.2025.104110_bib37","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/QAD.0000000000003245","article-title":"Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain","volume":"36","author":"Kauppinen","year":"2022","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.numecd.2025.104110_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QAD.0000000000003455","article-title":"Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model","volume":"37","author":"Perna","year":"2023","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0b013e328341f925","article-title":"Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care","volume":"25","author":"Crane","year":"2011","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.numecd.2025.104110_bib40","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cis1203","article-title":"SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine\/tenofovir from lamivudine\/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen","volume":"56","author":"Campo","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.numecd.2025.104110_bib41","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.3390\/jcm12113644","article-title":"Weight and metabolic outcomes in na\u00efve HIV patients treated with integrase inhibitor-based antiretroviral therapy: a systematic review and meta-analysis","volume":"12","author":"Valenzuela-Rodriguez","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.numecd.2025.104110_bib42","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9868","key":"10.1016\/j.numecd.2025.104110_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"issue":"10107","key":"10.1016\/j.numecd.2025.104110_bib44","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib45","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials","volume":"11","author":"Orkin","year":"2024","journal-title":"Lancet HIV"},{"issue":"17","key":"10.1016\/j.numecd.2025.104110_bib46","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-M\u00f8ller","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.numecd.2025.104110_bib48","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/ATVBAHA.108.179507","article-title":"The molecular mechanisms of HDL and associated vesicular trafficking mechanisms to mediate cellular lipid homeostasis","volume":"29","author":"Schmitz","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"16","key":"10.1016\/j.numecd.2025.104110_bib49","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.numecd.2025.104110_bib50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"25 Pt B","key":"10.1016\/j.numecd.2025.104110_bib51","first-page":"2889","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104110_bib52","unstructured":"Interim Guidance [Internet]. EACSociety. [cited 2025 Jan 14]. Available from: https:\/\/www.eacsociety.org\/guidelines\/interim-guidance\/."},{"issue":"34","key":"10.1016\/j.numecd.2025.104110_bib53","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12879-018-3162-1","article-title":"Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis","volume":"18","author":"Uthman","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0000000000002748","article-title":"Statin exposure and risk of cancer in people with and without HIV infection","volume":"35","author":"Bedimo","year":"2021","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.numecd.2025.104110_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232636","article-title":"Association between statin use, atherosclerosis, and mortality in HIV-infected adults","volume":"15","author":"Phan","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23102-2","article-title":"Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis","volume":"12","author":"Vigny","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2025.104110_bib58","doi-asserted-by":"crossref","DOI":"10.2991\/978-94-6463-556-0","article-title":"Advances in statin adverse reactions and the potential mechanisms: a systematic review","volume":"14","author":"Zeng","year":"2024","journal-title":"J Adv Res"},{"issue":"7","key":"10.1016\/j.numecd.2025.104110_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient\u2010reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"10.1016\/j.numecd.2025.104110_bib60","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199004193221602","article-title":"Mitochondrial myopathy caused by long-term zidovudine therapy","volume":"322","author":"Dalakas","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib61","article-title":"Myopathies secondary to anti-retroviral therapy in human immunodeficiency virus positive patients: a review","volume":"1","author":"Nikhil","year":"2015","journal-title":"Journal of HIV & Retro Virus"},{"issue":"12","key":"10.1016\/j.numecd.2025.104110_bib62","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.amjcard.2015.03.025","article-title":"A systematic review of the usefulness of statin therapy in HIV-infected patients","volume":"115","author":"Feinstein","year":"2015","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.numecd.2025.104110_bib63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2025.104110_bib64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40256-017-0222-7","article-title":"Recommendations for managing drug-drug interactions with statins and HIV medications","volume":"17","author":"Wiggins","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"issue":"7","key":"10.1016\/j.numecd.2025.104110_bib65","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkaa099","article-title":"Real-life management of drug-drug interactions between antiretrovirals and statins","volume":"75","author":"Courlet","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib66","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jmii.2024.01.003","article-title":"Under-utilization of statins among people with HIV who were aged 40 years or older","volume":"57","author":"Wu","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"issue":"10","key":"10.1016\/j.numecd.2025.104110_bib67","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/hiv.13150","article-title":"Statin gap in patients living with HIV: assessing dose appropriateness","volume":"22","author":"Pincus","year":"2021","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib68","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12879-021-05787-4","article-title":"Consistent use of lipid lowering therapy in HIV infection is associated with low mortality","volume":"21","author":"Drechsler","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib69","article-title":"Statin use and accessibility for patients living with HIV on a global scale","volume":"4","author":"Ramirez","year":"2025","journal-title":"JACC (J Am Coll Cardiol): Advances"},{"issue":"5","key":"10.1016\/j.numecd.2025.104110_bib70","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0000000000003175","article-title":"Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period","volume":"36","author":"Boccara","year":"2022","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib73","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","article-title":"Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways","volume":"60","author":"Koushki","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.numecd.2025.104110_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1339338","article-title":"Effects of statins beyond lipid-lowering agents in ART-treated HIV infection","volume":"15","author":"Mehraj","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.numecd.2025.104110_bib75","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.5114\/aoms\/158546","article-title":"The effects of statins on the function and differentiation of blood cells","volume":"19","author":"Chamani","year":"2023","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.numecd.2025.104110_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107614","article-title":"Statins and autoimmunity: state-of-the-art","volume":"214","author":"Dehnavi","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib77","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/CIRCULATIONAHA.104.502195","article-title":"Statin treatment after onset of sepsis in a murine model improves survival","volume":"112","author":"Merx","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib78","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/biomedicines11010159","article-title":"The many faces of immune activation in HIV-1 infection: a multifactorial interconnection","volume":"11","author":"Mazzuti","year":"2023","journal-title":"Biomedicines"},{"issue":"25","key":"10.1016\/j.numecd.2025.104110_bib79","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.numecd.2025.104110_bib80","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.numecd.2025.104110_bib81","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.numecd.2025.104110_bib82","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.phrs.2014.02.009","article-title":"Cardiovascular effects of statins, beyond lipid-lowering properties","volume":"88","author":"Mihos","year":"2014","journal-title":"Pharmacol Res"},{"issue":"11","key":"10.1016\/j.numecd.2025.104110_bib83","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/ATVBAHA.110.210500","article-title":"Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway","volume":"30","author":"Ota","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"26","key":"10.1016\/j.numecd.2025.104110_bib84","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"issue":"9670","key":"10.1016\/j.numecd.2025.104110_bib85","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib86","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12879-024-09050-4","article-title":"High-sensitivity C-reactive protein among people living with HIV on highly active antiretroviral therapy: a systemic review and meta-analysis","volume":"24","author":"Mabhida","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147484","article-title":"Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review","volume":"11","author":"Vos","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.numecd.2025.104110_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021843","article-title":"Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients","volume":"6","author":"Moore","year":"2011","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.numecd.2025.104110_bib89","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1097\/QAD.0000000000001167","article-title":"Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection","volume":"30","author":"Longenecker","year":"2016","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.numecd.2025.104110_bib90","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1501-1","article-title":"Tenofovir\/emtricitabine\/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients","volume":"15","author":"Calza","year":"2014","journal-title":"HIV Clin Trials"},{"issue":"5","key":"10.1016\/j.numecd.2025.104110_bib92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/aid.2020.0127","article-title":"Effect of statin use on inflammation and immune activation biomarkers in HIV-infected persons on effective antiretroviral therapy","volume":"37","author":"Hussain","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"10.1016\/j.numecd.2025.104110_bib93","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"Toribio","year":"2017","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.numecd.2025.104110_bib94","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/hrt.2004.056523","article-title":"Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor\u2010containing anti\u2010retroviral combination therapy: a randomised double blind crossover trial","volume":"92","author":"H\u00fcrlimann","year":"2006","journal-title":"Heart"},{"issue":"17","key":"10.1016\/j.numecd.2025.104110_bib95","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1097\/QAD.0000000000000475","article-title":"Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients","volume":"28","author":"Overton","year":"2014","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.numecd.2025.104110_bib96","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/QAD.0b013e328347c083","article-title":"Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load","volume":"25","author":"De Wit","year":"2011","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.numecd.2025.104110_bib97","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","volume":"16","author":"Liu","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"9","key":"10.1016\/j.numecd.2025.104110_bib98","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.3390\/ijerph20095668","article-title":"A systematic review and meta-analysis on the impact of statin treatment in HIV patients on antiretroviral therapy","volume":"20","author":"Mokgalaboni","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.numecd.2025.104110_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670566","article-title":"Contribution of adipose tissue to the chronic immune activation and inflammation associated with HIV infection and its treatment","volume":"12","author":"Bourgeois","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.numecd.2025.104110_bib100","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/82219","article-title":"Statins as a newly recognized type of immunomodulator","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104110_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052828","article-title":"Statin therapy and mortality in HIV-infected individuals; A Danish nationwide population-based cohort study","volume":"8","author":"Rasmussen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2025.104110_bib102","unstructured":"Liverpool HIV Interactions[Internet]. [cited 2025 Mar 10]. Available from: https:\/\/www.hiv-druginteractions.org\/checker."}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325002649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325002649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:35:04Z","timestamp":1758062104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325002649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":101,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0939475325002649"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104110","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dyslipidemia and statin use in people with HIV-1 infection: beyond the lipid-lowering effect","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104110"}}